Selectis Health ( (GBCS) ) has released a notification of late filing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Selectis Health, Inc. has filed a Form 12b-25, notifying investors of a delay in submitting its Form 10-Q (Quarter Report) for the quarter ended March 31, 2026. The company is an emerging growth issuer and remains otherwise current with all of its required U.S. Securities Exchange Act filings over the past year.
The company attributes the delay primarily to not having completed the preparation of its unaudited financial statements for the fiscal quarter. There is no indication of auditor changes, internal control failures, or special committee reviews; the issue appears to be timing and completion of the quarterly financial reporting process.
Selectis Health states that it expects to file the delayed Form 10-Q (Quarter Report) within the standard extension window allowed under SEC rules. Specifically, the company commits to filing the quarterly report no later than five calendar days after the original due date, which suggests a near-term resolution rather than a prolonged delay.
Management does not anticipate any significant change in results of operations compared with the same quarter of the prior fiscal year. No preliminary financial figures are provided, and the company’s statement about the absence of expected major changes should be viewed as forward-looking and subject to revision once the final Form 10-Q (Quarter Report) is filed.
The filing emphasizes that Selectis Health continues to pursue timely compliance with SEC reporting obligations despite this short-term delay. The notification is signed on behalf of the company by Vice President Krystal Eckhard on May 14, 2026, signaling executive-level oversight of the late-filing process and the ongoing effort to complete the quarter’s financial statements.
Spark’s Take on GBCS Stock
According to Spark, TipRanks’ AI Analyst, GBCS is a Underperform.
The overall stock score for GBCS is primarily impacted by its weak financial performance, characterized by negative profitability and high leverage. Technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio. The absence of earnings call data and corporate events does not affect the score.
To see Spark’s full report on GBCS stock, click here.
More about Selectis Health
Average Trading Volume: 1,869
Technical Sentiment Signal: Sell
Current Market Cap: $9.51M
For detailed information about GBCS stock, go to TipRanks’ Stock Analysis page.